This site is intended for U.S. healthcare professionals.

Visit Pfizer Medical

Menu

Close

Sign InLog Out
ProductsOrderMaterialsCo-pay Cards & Patient Savings OffersRequest SamplesHospital ProductsVaccinesPatient AssistancePfizer Oncology TogetherPfizer RxPathwaysExplore ContentEventsMaterialsVideosContact
Search

Menu

Menu

HomeEfficacy

Phase III Study Primary Endpoints

Success in ISGA: Clear or almost clearStudy Design

Phase III Study Secondary Endpoints

ISGA clear or almost clearTime to ISGA successPhase III Study: Other EndpointsPruritusQuality of life assessmentsInfant Study: Exploratory EndpointsISGA clear or almost clear%BSA, EASI & POEMSafety DataSafety DataPhase III Study Adverse Reactions*Pivotal trial & 48-week extension study Adverse ReactionsOpen-Label Safety Extension Study*Open-Label Safety Extension Study Rescue Therapy EndpointStudy designInfant Safety Study**Adverse ReactionsStudy design and DemographicsReal-World PatientsReal-world patient case reportsReal-world patient case studiesNana's experience with EucrisaBraxton's testimonialHand and fingerFace and neckOtherHand and finger5-yr-old Caucasian female - hands8-yr-old Caucasian female - hands15-yr-old Caucasian male - hand55-yr-old Caucasian female - hand64-yr-old Caucasian female - thumb70-yr-old Caucasian male - thumbFace and neck15-yr-old Caucasian male - chin18-yr-old Hispanic female - face and neck75-yr-old Caucasian male - faceOther39-yr-old Asian male - arm44-yr-old African American female - legs72-yr-old Caucasian female - legDosingSavings & SupportSavings & SupportEventsMaterialsVideosCopay CardsCost and Coverage
Prescribing InformationPatient Information Indication Patient Site
EUCRISA (crisaborole): A steroid-free optionFor the treatment of mild-to-moderate atopic dermatitis in patients 3 months and older Copay Cards

*Eligible patients pay as little as $10

 Download Copay Cards LoadingPatients enrolled in state or federally funded prescription insurance programs are not eligible to use this card. Savings up to $970 per tube. Annual savings up to $3,880. This card will be accepted only at participating pharmacies. This card is not health insurance. Order Samples

Register or sign in to check availability and request samples
 

 Order now Loading Infant Safety Study in patients 3 to <24 months of age

Learn more about a 28-day, single-arm, open-label safety study in 3 to <24 month old patients4

 Learn more Loading“Sometimes I don’t even want to look at my own skin”

Nana is a dancer who has had mild-to-moderate atopic dermatitis for more than 30 years

 View Nana's story Loading Efficacy

EUCRISA has proven efficacy across all pivotal trial primary and secondary endpoints in patients aged 2 years and up1,2

 Learn more Loading Safety Data

Learn more about the safety data of EUCRISA from the 4-week pivotal trials and open-label safety extension study1,3

 View safety data Loading Dosing

EUCRISA can be applied to the skin anywhere on the face and body1

For topical use only. Not for ophthalmic, oral or intravaginal use Understand more LoadingReferencesEUCRISA® (crisaborole) Full Prescribing Information. April 2020.Paller AS, Tom WL, Lebwohl MG, et al. Efficacy and safety of crisaborole ointment, a novel, nonsteroidal phosphodiesterase 4 (PDE4) inhibitor for the topical treatment of atopic dermatitis (AD) in children and adults. J Am Acad Dermatol. 2016;75(3):494-503.e4.Eichenfield LF, Tom WL, Berger TJ, et al. Guidelines of care for the management of atopic dermatitis: section 2. Management and treatment of atopic dermatitis with topical therapies. J Am Acad Dermatol. 2014;71(1)116-132.Schlessinger J, Shepard JS, Gower R, et al. Safety, effectiveness, and pharmacokinetics of crisaborole in infants aged 3 to <24 months with mild-to-moderate atopic dermatitis: a phase IV open-label study (CrisADe CARE 1). Am J Clin Dermatol. 2020. 21:275-284.

To report an adverse event, please call 1-800-438-1985

Pfizer for Professionals 1-800-505-4426

This site is intended only for U.S. healthcare professionals. The products discussed in this site may have different product labeling in different countries. The information provided is for educational purposes only.

© 2022 Pfizer Inc. All rights reserved.

PP-EUC-USA-0032
You are now leaving Pfizer You are now leaving a Pfizer operated website. Links to all outside sites are provided as a resource to our visitors. Pfizer accepts no responsibility for the content of sites that are not owned and operated by Pfizer. 

PP-EUC-USA-0032
INDICATION

EUCRISA (crisaborole) is indicated for topical treatment of mild-to-moderate atopic dermatitis in adult and pediatric patients 3 months of age and older.

EUCRISA is for topical use only and is not for ophthalmic, oral, or intravaginal use. For more information, please view the full prescribing information here.

Important Safety Information

Contraindications

EUCRISA is contraindicated in patients with known hypersensitivity to crisaborole or any component of the formulation.

Warnings and Precautions

Hypersensitivity reactions, including contact urticaria, have occurred in patients treated with EUCRISA and should be suspected in the event of severe pruritus, swelling, and erythema at the application site or at a distant site. Discontinue EUCRISA immediately and initiate appropriate therapy if signs and symptoms of hypersensitivity occur.

Adverse Reactions

The most common treatment-related adverse reaction occurring in clinical trials was application site pain, such as burning or stinging.

Please see Full Prescribing Information and Patient Information

Indication EUCRISA is indicated for topical treatment of mild-to-moderate atopic dermatitis in adult and pediatric patients 3 months of age and older.